Innovator国际已开发动力缓冲主动型ETF-3月 IMAR 深 沪
已收盘 05-08 16:00:00 美东时间
30.1909
+0.145
+0.48%
华盛通- 最 高30.23
- 今 开30.20
- 成交量 97.24万股
- 最 低 30.13
- 昨 收 30.0457
- 总市值 9585.61万
- 52周最高 30.54
- 市盈率 静 --
- 换手率 30.63%
- 52周最低 27.54
- 委 比 -33.33%
- 总股本 317.50万
- 历史最高 30.54
- 量 比 1.93
- 振 幅 0.33%
- 历史最低 24.6018
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lithuania unveils first HIMARS launchers as defense ties with Lockheed deepen
Lithuania has taken delivery of its first High Mobility Artillery Rocket System (HIMARS) launchers, marking a step forward in the country’s military modernization and its integration with NATO forces....
05-06 03:11
U.S. awards over $2B in defense contracts across Army, Navy, Air Force and DLA
The U.S. Department of Defense on Wednesday awarded more than $2 billion in contracts spanning missile systems, armoured vehicle sensors, aircraft support and logistics across the Army, Navy, Air Forc...
04-30 05:21
Lockheed Martin wins $1.13B Army deal for HIMARS launcher production
Lockheed Martin (LMT) won an undefinitized and not-to-exceed contract value of $1.13B for producing HIMARS M142 launchers under full-rate production Lot 17. The order is meant to meet urgent U.S. Army...
04-30 05:14
Transcript: Lockheed Martin Q1 2026 Earnings Conference Call
Lockheed Martin (NYSE:LMT) reported first-quarter financial results on Thursday...
04-23 21:51
BRIEF-Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike In Head-To-Head Study
BRIEF-Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike In Head-To-Head Study April 18 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: ESCMID: SANOFI'S NUVAXOVID COVID-19 VACCINE SHOWED BETTER TOLERABILITY THAN MNEXSPIKE IN HEAD-TO-HEAD STUDY SANOFI - STUDY MET PRIMARY
04-18 18:42
UPDATE 2-Lithuania says the US may delay ammunition deliveries due to Iran war
UPDATE 2-Lithuania says the US may delay ammunition deliveries due to Iran war Adds context in paragraph 3, background in paragraphs 5-10 By Andrius Sytas and Janis Laizans VILNIUS/TALLINN, April 17 (Reuters) - The United States has informed Lithuania of possible delays in the delivery of ammunition
04-17 18:30
BRIEF-Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset
BRIEF-Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset April 1 (Reuters) - Medicus Pharma Ltd MDCX.O : MEDICUS PHARMA LTD CLARIFIES POSITIVE SKINJECT PHASE 2 DATASET MEDICUS PHARMA LTD - DATASET SUPPORTS SKINJECT DEVELOPMENT, REGULATORY DISCUSSIONS, AND STRATEGIC PARTNERSHIPS MEDICUS P
04-01 20:02
BRIEF-Trinity Capital Provides $50 Million In Growth Capital To Sage Health To Expand Senior-Focused Primary Care Wellness Centers
BRIEF-Trinity Capital Provides $50 Million In Growth Capital To Sage Health To Expand Senior-Focused Primary Care Wellness Centers Trinity Capital Inc TRIN.O : TRINITY CAPITAL PROVIDES $50 MILLION IN GROWTH CAPITAL TO SAGE HEALTH TO EXPAND SENIOR-FOCUSED PRIMARY CARE WELLNESS CENTERS Source text: ID
03-27 21:00
BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer
BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer March 25 (Reuters) - US FDA: FDA APPROVES RELACORILANT WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER F
03-25 22:59
BRIEF-Bayer Says Finerenone Meets Primary Endpoint In Investigational Phase III FIND-CKD Study
BRIEF-Bayer Says Finerenone Meets Primary Endpoint In Investigational Phase III FIND-CKD Study March 16 (Reuters) - BAYER AG BAYGn.DE : KERENDIA® (FINERENONE) MEETS PRIMARY ENDPOINT IN INVESTIGATIONAL PHASE III FIND-CKD STUDY IN PATIENTS WITH NON-DIABETIC CHRONIC KIDNEY DISEASE DEMONSTRATING A STATI
03-16 15:32
